News & Events

Other Events. On June 1, 2026, Voyager Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for VY1706, the Company’s investigational tau silencing gene therapy developed to target intracellular and extracellular tau for Alzheimer’s disease (“AD”). The Company plans to initiate a multi-site, open-label, dose-escalation clinical trial of VY1706, which is expected to begin dosing in the second half of 2026.…

shall be deemed to be furnished, and not filed: ​ ​ ​ ​ Exhibit No. ​ Description ​ ​ ​ 99.1 ​ Press release dated May 7, 2026 entitled “Voyager Reports First Quarter 2026 Financial and Operating Results”. 104 ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). ​ ​ ​ ​ ​ 2 SIGNATURES ​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto dul…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Chief Financial Officer On April 15, 2026, Nathan Jorgensen, Ph.D. notified Voyager Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company and any of its subsidiaries, effective May 8, 2026 (the effective t…

shall be deemed to be furnished, and not filed: ​ ​ ​ ​ Exhibit No. ​ Description ​ ​ ​ 99.1 ​ Press release dated March 9, 2026 entitled “Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results”. 104 ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). ​ ​ ​ ​ ​ 2 SIGNATURES ​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersi…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Chief Medical Officer On February 9, 2026, Toby Ferguson, M.D., Ph.D. notified Voyager Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Medical Officer of the Company and from any and all other positions he holds with the Company and any of its subsidiaries, effective February 20, 2026, to pursu…

of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 hereto, the Company is not making an admission as to the materiality of any information herein. The information contained in this Current Report on Form 8-K is intended to be considered in the context of more complete information included in the Company’s filings with the SEC and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no…

shall be deemed to be furnished, and not filed: ​ ​ ​ ​ Exhibit No. ​ Description ​ ​ ​ 99.1 ​ Press release dated November 10, 2025 entitled “Voyager Reports Third Quarter 2025 Financial and Operating Results”. 104 ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). ​ ​ ​ ​ ​ 2 SIGNATURES ​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereun…

shall be deemed to be furnished, and not filed: ​ ​ ​ ​ Exhibit No. ​ Description ​ ​ ​ 99.1 ​ Press release dated August 6, 2025 entitled “Voyager Reports Second Quarter 2025 Financial and Operating Results”. 104 ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). ​ ​ ​ ​ ​ 2 SIGNATURES ​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto…

shall be deemed to be furnished, and not filed: ​ ​ ​ ​ Exhibit No. ​ Description ​ ​ ​ 99.1 ​ Press release dated May 6, 2025 entitled “Voyager Reports First Quarter 2025 Financial and Operating Results”. 104 ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). ​ ​ ​ ​ ​ 2 SIGNATURES ​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto dul…

shall be deemed to be furnished, and not filed: ​ ​ ​ ​ Exhibit No. ​ Description ​ ​ ​ 99.1 ​ Press release dated March 11, 2025 entitled “Voyager Therapeutics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results”. 104 ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). ​ ​ ​ ​ ​ 2 SIGNATURES ​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf…

Other Events ALS Program Update On February 11, 2025, Voyager Therapeutics, Inc. (the “Company”) announced that it has decided to assess alternate payloads related to its superoxide dismutase 1 silencing gene therapy program for amyotrophic lateral sclerosis (the “SOD1 ALS Program”). Emerging three-month non-human primate (NHP) data suggest that an alternate payload would be necessary to achieve the Company’s desired product profile for the SOD1 ALS Program. No changes are planned to the nove…